Avantor, Inc. (NYSE:AVTR) Shares Bought by Whittier Trust Co.

Whittier Trust Co. lifted its position in shares of Avantor, Inc. (NYSE:AVTR) by 5.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 199,715 shares of the company’s stock after purchasing an additional 9,449 shares during the period. Whittier Trust Co.’s holdings in Avantor were worth $4,234,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Versant Capital Management Inc raised its position in shares of Avantor by 2,003.6% during the 2nd quarter. Versant Capital Management Inc now owns 1,157 shares of the company’s stock worth $25,000 after purchasing an additional 1,102 shares during the last quarter. Blue Trust Inc. raised its holdings in Avantor by 1,830.3% in the 2nd quarter. Blue Trust Inc. now owns 1,467 shares of the company’s stock valued at $31,000 after acquiring an additional 1,391 shares during the last quarter. Gladius Capital Management LP acquired a new position in Avantor in the 4th quarter valued at $42,000. Montag A & Associates Inc. purchased a new stake in shares of Avantor during the 4th quarter valued at $43,000. Finally, TFO Wealth Partners LLC grew its stake in shares of Avantor by 203,100.0% during the 4th quarter. TFO Wealth Partners LLC now owns 2,032 shares of the company’s stock valued at $46,000 after buying an additional 2,031 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

Avantor Stock Up 1.2 %

Avantor stock traded up $0.30 during mid-day trading on Thursday, reaching $25.86. The company’s stock had a trading volume of 731,323 shares, compared to its average volume of 6,739,972. The company has a market capitalization of $17.57 billion, a price-to-earnings ratio of 65.54, a price-to-earnings-growth ratio of 2.71 and a beta of 1.32. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.05 and a current ratio of 1.59. The business’s 50 day simple moving average is $23.26 and its 200 day simple moving average is $24.09. Avantor, Inc. has a 12 month low of $16.63 and a 12 month high of $28.00.

Avantor (NYSE:AVTR) last announced its quarterly earnings results on Friday, July 26th. The company reported $0.25 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $0.02. The firm had revenue of $1.70 billion during the quarter, compared to analysts’ expectations of $1.70 billion. Avantor had a net margin of 5.28% and a return on equity of 12.40%. As a group, research analysts anticipate that Avantor, Inc. will post 1.01 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Evercore ISI cut their target price on shares of Avantor from $28.00 to $27.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. Morgan Stanley increased their price objective on shares of Avantor from $28.00 to $29.00 and gave the company an “overweight” rating in a report on Monday, July 29th. Stifel Nicolaus raised their target price on shares of Avantor from $27.00 to $28.00 and gave the stock a “buy” rating in a report on Monday, July 29th. Citigroup downgraded shares of Avantor from a “buy” rating to a “neutral” rating and reduced their price target for the company from $30.00 to $23.00 in a research report on Wednesday, July 10th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $31.00 target price on shares of Avantor in a research report on Monday, July 29th. Four investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $27.40.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.